Search

Your search keyword '"Borlongan C.V."' showing total 3 results
Start Over Author "Borlongan C.V." Topic mesenchymal stem cells
3 results on '"Borlongan C.V."'

1. Meeting report of the first conference of the International Placenta Stem Cell Society (IPLASS).

Author

Parolini, O., Alviano, F., Betz, A.G., Bianchi, D.W., Götherström, C., Manuelpillai, U., Mellor, A.L., Ofir, R., Ponsaerts, P., Scherjon, S.A., Weiss, M.L., Wolbank, S., Wood, K.J., and Borlongan, C.V.

Subjects
STEM cells, PLACENTA, FETAL membranes, BIOLOGICAL societies, MEETINGS, LECTURES & lecturing, IMMUNOREGULATION, MESENCHYMAL stem cells
Abstract

Abstract: The International Placenta Stem Cell Society (IPLASS) was founded in June 2010. Its goal is to serve as a network for advancing research and clinical applications of stem/progenitor cells isolated from human term placental tissues, including the amnio-chorionic fetal membranes and Wharton’s jelly. The commitment of the Society to champion placenta as a stem cell source was realized with the inaugural meeting of IPLASS held in Brescia, Italy, in October 2010. Officially designated as an EMBO-endorsed scientific activity, international experts in the field gathered for a 3-day meeting, which commenced with “Meet with the experts” sessions, IPLASS member and board meetings, and welcome remarks by Dr. Ornella Parolini, President of IPLASS. The evening’s highlight was a keynote plenary lecture by Dr. Diana Bianchi. The subsequent scientific program consisted of morning and afternoon oral and poster presentations, followed by social events. Both provided many opportunities for intellectual exchange among the 120 multi-national participants. This allowed a methodical and deliberate evaluation of the status of placental cells in research in regenerative and reparative medicine. The meeting concluded with Dr. Parolini summarizing the meeting’s highlights. This further prepared the fertile ground on which to build the promising potential of placental cell research. The second IPLASS meeting will take place in September 2012 in Vienna, Austria. This meeting report summarizes the thought-provoking lectures delivered at the first meeting of IPLASS. [Copyright &y& Elsevier]

Published
2011
Full Text
View/download PDF

2. Amniotic membrane and amniotic cells: Potential therapeutic tools to combat tissue inflammation and fibrosis?

Author

Manuelpillai, U., Moodley, Y., Borlongan, C.V., and Parolini, O.

Subjects
CELL membranes, AMNIOTIC liquid, UMBILICAL cord, PLACENTA, THERAPEUTICS, INFLAMMATION, FIBROSIS, MESENCHYMAL stem cells
Abstract

Abstract: In addition to the placenta, umbilical cord and amniotic fluid, the amniotic membrane is emerging as an immensely valuable and easily accessible source of stem and progenitor cells. This concise review will focus on the stem/progenitor cell properties of human amniotic epithelial and mesenchymal stromal cells and evaluate the effects exerted by these cells and the amniotic membrane on tissue inflammation and fibrosis. [Copyright &y& Elsevier]

Published
2011
Full Text
View/download PDF

3. Toward Cell Therapy Using Placenta-Derived Cells: Disease Mechanisms, Cell Biology, Preclinical Studies, and Regulatory Aspects at the Round Table

Author

Cesar V. Borlongan, Giacomo Lanzoni, Stephen C. Strom, Maddalena Soncini, Ornella Parolini, Sankar Venkatachalam, Massimo Dominici, Steffen M. Zeisberger, Maria Luisa Nolli, Bing Liu, Peter De Waele, Daniel Surbek, Francesco Alviano, Diana Boraschi, Susanne Wolbank, Luca Romagnoli, Cosimo De Bari, Fabio Marongiu, David C. Hess, Andy Zeitlin, Stefan Mohr, Abraham Solomon, Werner Falk, Andreas H. Zisch, Marco Evangelista, Peter Ponsaerts, Colin McGuckin, Irene Bergwerf, Racheli Ofir, Simone Hennerbichler, University of Zurich, Parolini, O, Parolini O., Alviano F., Berwerf I., Boraschi D., De Bari C., De Waele P., Dominici M., Evangelista M., Falk W., Hennerbichler S., Hess D.C., Lanzoni G., Liu B., Marongiu F., McGuckin C., Mohr S., Nolli M.L., Ofir R., Ponsaerts P., Romagnoli L., Solomon A., Soncini M., Strom S., Surbek D., Venkatachalam S., Wolbank S., Zeisberger S., Zeitlin A., Zisch A., and Borlongan C.V.

Subjects
Cell type, HUMAN TERM PLACENTA, AMNIOTIC EPITHELIAL-CELLS, Placenta, 2720 Hematology, Cell- and Tissue-Based Therapy, 610 Medicine & health, Cell Separation, Biology, Regenerative medicine, 1309 Developmental Biology, 1307 Cell Biology, Cell therapy, Pregnancy, Settore BIO/13 - BIOLOGIA APPLICATA, Animals, Humans, Good manufacturing practice, Disease Models, Animal, Female, Inflammation, Stem Cells, Hematology, Developmental Biology, Cell Biology, 10026 Clinic for Obstetrics, Animal, Disease mechanisms, MESENCHYMAL STEM CELLS, Clinical reality, 10022 Division of Surgical Research, Round table, Risk analysis (engineering), Disease Models, Immunology, Human medicine, cell therapy, Stem cell
Abstract

Among the many cell types that may prove useful to regenerative medicine, mounting evidence suggests that human term placenta-derived cells will join the list of significant contributors. In making new cell therapy-based strategies a clinical reality, it is fundamental that no a priori claims are made regarding which cell source is preferable for a particular therapeutic application. Rather, ongoing comparisons of the potentiality and characteristics of cells from different sources should be made to promote constant improvement in cell therapies, and such comparisons will likely show that individually tailored cells can address disease-specific clinical needs. The principle underlying such an approach is resistance to the notion that comprehensive characterization of any cell type has been achieved, neither in terms of phenotype nor risks-to-benefits ratio. Tailoring cell therapy approaches to specific conditions also requires an understanding of basic disease mechanisms and close collaboration between translational researchers and clinicians, to identify current needs and shortcomings in existing treatments. To this end, the international workshop entitled Placenta-derived stem cells for treatment of inflammatory diseases: moving toward clinical application was held in Brescia, Italy, in March 2009, and aimed to harness an understanding of basic inflammatory mechanisms inherent in human diseases with updated findings regarding biological and therapeutic properties of human placenta-derived cells, with particular emphasis on their potential for treating inflammatory diseases. Finally, steps required to allow their future clinical application according to regulatory aspects including good manufacturing practice (GMP) were also considered. In September 2009, the International Placenta Stem Cell Society (IPLASS) was founded to help strengthen the research network in this field.

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results